Abbott Laboratories segment revenues 2017-2025| ��ƽ��

Abbott Laboratories' segment revenues from 2017 to 2025 (in million U.S. dollars)

Characteristic	Pharmaceuticals	Nutritionals	Diagnostics	Medical Devices	Other
2017	4,287	6,925	5,616	10,325	237
2018	4,422	7,229	7,495	11,370	62
2019	4,486	7,409	7,713	12,239	57
2020	4,303	7,647	10,805	11,787	66
2021	4,718	8,294	15,644	14,367	52
2022	4,912	7,459	16,584	14,687	11
2023	5,066	8,154	9,988	16,887	14
2024	5,194	8,413	9,341	18,986	16
2025	5,536	8,451	8,937	21,387	17

Download

Source

Show detailed source information?

Already a member?

Source

Release date

February 2026

More information

Region

Worldwide

Survey time period

2017 to 2025

Citation formats

Abbot Laboratories is an international medtech and pharmaceutical company headquartered in Chicago, Illinois. In 2013, Abbott Laboratories was split into two companies: Abbot (medical products) and AbbVie (research-based pharmaceuticals). As of 2025, the medical devices segment was the largest segment within the company and generated over 21 billion U.S. dollars in revenues. Abbot’s diagnostics segment was, prior to 2024, the largest generator of revenue but dropped to around nine billion U.S. dollars in 2025.

Abbott’s company profile

Abbott Laboratories was founded in 1888 in Chicago, where the company has remained since. The company operates in around 160 countries globally, covering therapeutic areas such as diabetes, diagnostics, nutrition and cardiovascular disease. The number of employees at Abbot Laboratories (Abbot and AbbVie) has increased over the last several years. The revenues of Abbott declined around the time the company was split in 2013 but has increased significantly recently.

Abbott’s global positioning

Abbot Laboratories is among the top global health companies based on revenue. Furthermore, AbbVie, Abbott Laboratories’ spin-off company, was ranked second among the top global pharmaceutical companies based on prescription sales.